Caitlin Cameron, Chairman of the Board and Chief Executive Officer. Ms. Cameron is a highly-accomplished senior executive with 30 years’ cross-industry expertise in the Life Sciences, Biotech, Technology, and IT industries. She is a specialist in building successful start-up companies and taking them through to successful exit. Previously, she held Chair and CEO positions at several Life Sciences and IT companies, building successful businesses and organizations, creating value and maximizing potential in a very short period of time. In addition, she has built organizations known for employee satisfaction, including being selected for the 100 Best Places to Work in Washington.
Rhonda F. Rhyne, Board Member. Ms. Rhyne has more than 25 years of experience in health care with both public and private industry companies, as well as experience as a clinical pharmacist. She was previously President of CardioDynamics, a publicly-traded medical device company sold to SonoSite Inc. in 2009. Prior to CardioDynamics, Ms. Rhyne held positions of President & CEO, VP of Sales and Marketing, and Board Director at Culture Technology, Inc., a privately-held biotechnology company, as well as positions at GE Health Care and Cardiac Science. Rhonda is principal of Rhyne Life Sciences Consulting, a consultancy practice focused on emerging life science technologies. She also serves on the Board of Directors and Audit Committee for La Jolla Institute of Allergy and Immunology, Deeds from the Heart and Washington State University College of Pharmacy Dean’s Advisory Council.
Marion R. Foote (“Robin”), Board Member. Ms. Foote is an experienced business executive and consultant, who is now fully engaged as a private investor and corporate director. In her corporate career, she ultimately served as Group EVP/CMO for Bank of America. In previous positions, she led an ever-expanding portfolio of specialized financial services and strategic initiatives for First Chicago. She began her consulting career with McKinsey & Company, and, in 2001, established her own firm (Randolph Partners) which she subsequently merged into Novantas, where she served as a partner through 2012. Throughout her career, Ms. Foote has focused on creating customer and shareholder value. Collectively, she has led development and implementation of analytically-driven strategic initiatives and programs worth billions in bottom-line improvement. Ms. Foote serves on the Boards of Avalara, Inc., and Saturna Trust Company, as well as the PeaceHealth St. Joseph Medical Center Foundation and St. Paul’s Academy. She is a past Director of several other public and private companies, all of which have been successfully sold or merged.
Harris Brody, Board Member. Mr. Brody is a Partner of Blue Fog Capital, a private investment company focused on equity and debt investments in early-stage and lower-middle market companies. Mr. Brody’s transactional experience with Blue Fog Capital, J.P. Morgan, and Prudential Financial includes more than $4 billion of private equity investment and $50 billion of M&A activity across a variety of sectors, including technology, healthcare, consumer and retail, industrials, and real estate. Mr. Brody brings a wide variety of experience in strategy, general management, finance, accounting, and operations to the portfolio companies he works with and partners closely and constructively with management to maximize shareholder value. Previously, Mr. Brody spent time in industry at the Clorox Company in a marketing and general management focused role on the Kingsford Charcoal and Combat Insecticides businesses.
Mark A. Moehring, PhD, CTO and Vice President – Research and Development, Board Member. Dr. Moehring is a recognized leader in the field of ultrasound with over three decades of experience in medical ultrasound instrument design. He is an internationally recognized expert in medical ultrasound and signal processing. His research and product development focus has been in the field of Doppler ultrasound with primary emphasis in diagnostic and therapeutic cranial and otitis media applications. Dr. Moehring is the inventor of 16 issued patents in ultrasound and hemodynamic monitoring technology.
George A. Gates MD, Founder, Chief Medical Officer, Board Member. Dr. Gates is a nationally recognized clinician and medical researcher in his field, with substantial experience in the diagnosis and treatment of otitis media. Dr. Gates is an otolaryngologist and neurotologist, and is currently an Emeritus Professor at the University of Washington (UW) and former director of the Virginia Merrill Bloedel Hearing Research Center at the UW. In his career, he has authored over 220 peer-reviewed published articles directly related to our medical area of interest. Dr. Gates is the inventor of our technology.